Pathophysiology and therapeutic options in primary immune thrombocytopenia.
作者信息
Stasi Roberto
机构信息
Department of Haematology, St George's Hospital, Blackshaw Road, London, United Kingdom.
出版信息
Blood Transfus. 2011 Jul;9(3):262-73. doi: 10.2450/2010.0080-10. Epub 2010 Nov 26.
Abstract
摘要
相似文献
1
Pathophysiology and therapeutic options in primary immune thrombocytopenia.
Blood Transfus. 2011 Jul;9(3):262-73. doi: 10.2450/2010.0080-10. Epub 2010 Nov 26.
2
An update on the pathophysiology of immune thrombocytopenia.
Curr Opin Hematol. 2020 Nov;27(6):423-429. doi: 10.1097/MOH.0000000000000612.
3
Pathogenesis of chronic immune thrombocytopenic purpura.
Curr Opin Hematol. 2007 Sep;14(5):511-4. doi: 10.1097/MOH.0b013e3282ba5552.
4
[Platelet antigens, antibodies and related clinical conditions].
Sangre (Barc). 1991 Oct;36(5):395-415.
5
[The pathogenesis of primary immune thrombocytopenia].
Ugeskr Laeger. 2011 Jan 24;173(4):274-7.
6
A case of 'auto-immune thrombocytopenic purpura' serologically similar to post-transfusion purpura.
Vox Sang. 1992;62(2):108-12. doi: 10.1111/j.1423-0410.1992.tb01180.x.
7
[Determination of antigens of anti-thrombocyte antibodies in patients with different forms of thrombocytopenia].
Biull Eksp Biol Med. 1998 May;125(5):596-600.
8
Advances in immunopathogenesis of adult immune thrombocytopenia.
Front Med. 2013 Dec;7(4):418-24. doi: 10.1007/s11684-013-0297-8. Epub 2013 Nov 21.
9
Antiplatelet antibodies in childhood idiopathic thrombocytopenic purpura.
Am J Hematol. 1996 Apr;51(4):328. doi: 10.1002/(SICI)1096-8652(199604)51:4<328::AID-AJH14>3.0.CO;2-A.
10
Is immune thrombocytopenic purpura (ITP) due to natural antibodies specific to platelets?
Eur J Haematol. 1996 Mar;56(3):178-80. doi: 10.1111/j.1600-0609.1996.tb01339.x.
引用本文的文献
1
Influence of the Immune Checkpoint Inhibitors on the Hemostatic Potential of Blood Plasma.
Transfus Med Hemother. 2024 Aug 21;52(2):120-131. doi: 10.1159/000535926. eCollection 2025 Apr.
2
Immune Thrombocytopenic Purpura (ITP) With Ulcerative Colitis (UC).
Cureus. 2024 Oct 31;16(10):e72778. doi: 10.7759/cureus.72778. eCollection 2024 Oct.
3
Recent advances in the management of immune thrombocytopenic purpura (ITP): A comprehensive review.
Medicine (Baltimore). 2024 Jan 19;103(3):e36936. doi: 10.1097/MD.0000000000036936.
4
Immune thrombocytopenic purpura and legionella infection: A case report highlighting the association.
IDCases. 2022 Feb 1;27:e01439. doi: 10.1016/j.idcr.2022.e01439. eCollection 2022.
5
Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia.
Cells. 2021 Dec 1;10(12):3386. doi: 10.3390/cells10123386.
6
ESPED survey on newly diagnosed immune thrombocytopenia in childhood: how much treatment do we give?
Mol Cell Pediatr. 2021 Sep 5;8(1):11. doi: 10.1186/s40348-021-00121-z.
7
Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach.
Int J Mol Sci. 2021 Jun 27;22(13):6907. doi: 10.3390/ijms22136907.
8
Efficacy and Safety of IQYMUNE®, a Ten Percent Intravenous Immunoglobulin in Adult Patients With Chronic, Primary Immune Thrombocytopenia.
J Hematol. 2018 Sep;7(3):87-95. doi: 10.14740/jh385w. Epub 2018 Sep 1.
9
Human platelet antigens and primary immune thrombocytopenia.
Rev Bras Hematol Hemoter. 2017 Apr-Jun;39(2):95-97. doi: 10.1016/j.bjhh.2017.02.008. Epub 2017 Mar 11.
10
Advances in Diagnosis and Treatments for Immune Thrombocytopenia.
Clin Med Insights Blood Disord. 2016 Jul 17;9:15-22. doi: 10.4137/CMBD.S39643. eCollection 2016.
本文引用的文献
1
Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study.
Lancet. 2011 Jan 29;377(9763):393-402. doi: 10.1016/S0140-6736(10)60959-2. Epub 2010 Aug 23.
2
Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.
Blood. 2010 Feb 4;115(5):1037-48. doi: 10.1182/blood-2008-10-183558. Epub 2009 Dec 8.
3
Infectious causes of chronic immune thrombocytopenia.
Hematol Oncol Clin North Am. 2009 Dec;23(6):1275-97. doi: 10.1016/j.hoc.2009.08.009.
4
Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis.
Haematologica. 2010 Jan;95(1):65-70. doi: 10.3324/haematol.2009.007542. Epub 2009 Aug 27.
5
Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim.
Blood. 2009 Oct 29;114(18):3748-56. doi: 10.1182/blood-2009-05-224766. Epub 2009 Aug 11.
6
Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database.
Br J Haematol. 2009 Apr;145(2):235-44. doi: 10.1111/j.1365-2141.2009.07615.x. Epub 2009 Feb 24.
7
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
Lancet. 2009 Feb 21;373(9664):641-8. doi: 10.1016/S0140-6736(09)60402-5.
8
Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia.
Blood. 2009 Apr 23;113(17):4086-93. doi: 10.1182/blood-2008-09-181073. Epub 2008 Nov 20.
9
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.
Blood. 2009 Mar 12;113(11):2386-93. doi: 10.1182/blood-2008-07-162503. Epub 2008 Nov 12.
10
Massive platelet transfusion is a rapidly effective emergency treatment in patients with refractory autoimmune thrombocytopenia.
Thromb Haemost. 2008 Nov;100(5):762-5.
Zotero 插件